Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOM230 Extension Study in Cushing's Disease and Acromegaly (China)
CTR20150117Phase 4Terminated
- Sponsor
- Novartis
- Start
- Apr 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of pasireotide LAR in Corticotropin adenoma (ACTHoma), acromegaly, sponsored by Novartis. Started Apr 2015; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
Corticotropin adenoma (ACTHoma)acromegaly
Beyond the preview
Go deeper on CTR20150117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150117.